Expert Review of Anticancer Therapy最新文献_第9页

Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis. 同时使用H1抗组胺药可改善接受免疫检查点抑制剂治疗的癌症患者的生存结局：一项系统回顾和荟萃分析。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-01-21 DOI: 10.1080/14737140.2026.2617952

Francisco Cezar Aquino de Moraes, Pedro Henrique de Souza Wagner, Rosario Dominguez Crespo Hirata, Rommel Mario Rodriguez Burbano, Mario Hiroyuki Hirata

{"title":"Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis.","authors":"Francisco Cezar Aquino de Moraes, Pedro Henrique de Souza Wagner, Rosario Dominguez Crespo Hirata, Rommel Mario Rodriguez Burbano, Mario Hiroyuki Hirata","doi":"10.1080/14737140.2026.2617952","DOIUrl":"10.1080/14737140.2026.2617952","url":null,"abstract":"Introduction: The rapid progress of immuno-oncology has transformed cancer pharmacotherapy through immune checkpoint inhibitors (ICIs); however, only a minority of patients experience durable benefits. Recent evidence suggests that concomitant administration of H1 antihistamines may synergistically enhance ICI efficacy by modulating the tumor immune microenvironment. This meta-analysis evaluated the association between H1 antihistamine use and outcomes in cancer patients undergoing ICI therapy.Methods: Comprehensive searches were conducted in PubMed, Embase, and Web of Science to identify studies comparing overall survival (OS) and progression-free survival (PFS) between ICI users with and without H1 antihistamines. Pooled hazard ratios (HRs) were calculated using a random-effects model (REML) in R software (v4.4.2).Results: Six retrospective cohort studies encompassing 2166 patients (417 antihistamine users and 1749 non-users) were included, primarily involving lung cancer (34.5%) and melanoma (13%). H1 antihistamine use was significantly associated with improved OS (HR = 0.64; 95% CI 0.42-0.97; p = 0.035) and PFS (HR = 0.54; 95% CI 0.44-0.66; p < 0.001).Conclusions: These findings indicate that H1 receptor blockade may potentiate the therapeutic efficacy of ICIs, resulting in better survival and delayed disease progression. The integration of antihistamines with ICIs may represent a promising and cost-effective adjunct strategy in cancer immunotherapy.Registration: PROSPERO (CRD420251207396).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"917-927"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence in bladder cancer management: a narrative review of diagnostic and surgical advances and current limitations. 人工智能在膀胱癌治疗中的应用：诊断和手术进展及当前局限性的叙述性回顾。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-02-08 DOI: 10.1080/14737140.2026.2619018

Gaetano Salzano, Alessio Digiacomo, Guglielmo Dello Stritto, Angelo Orsini, Riccardo De Archangelis, Rossella Cicchetti, Peppino Lannutti, Simone Ferretti, Luigi Schips, Michele Marchioni

{"title":"Artificial intelligence in bladder cancer management: a narrative review of diagnostic and surgical advances and current limitations.","authors":"Gaetano Salzano, Alessio Digiacomo, Guglielmo Dello Stritto, Angelo Orsini, Riccardo De Archangelis, Rossella Cicchetti, Peppino Lannutti, Simone Ferretti, Luigi Schips, Michele Marchioni","doi":"10.1080/14737140.2026.2619018","DOIUrl":"10.1080/14737140.2026.2619018","url":null,"abstract":"Introduction: Bladder cancer (BC) is associated with high recurrence and progression rates that require intensive surveillance. In this context, Artificial Intelligence (AI) offers promising tools to enhance diagnostic, prognostic, and surgical pathways.Areas covered: This narrative review critically examines the current state of AI applications across the bladder cancer care focusing on diagnostic, prognostic and surgical domains. A comprehensive literature search was conducted to identify relevant studies. Key topics include radiomics in computed tomography (CT) and magnetic resonance imaging (MRI), radiogenomics, pathomics and AI-assisted cystoscopy. Furthermore, the role of AI in preoperative planning, intraoperative navigation and surgical training is discussed highlighting its integration in robotic and endoscopic procedures.Expert opinion: AI is rapidly redefining bladder cancer management through multimodal data integration and predictive modeling. While current evidence demonstrates high diagnostic and prognostic performance, clinical implementation remains limited by heterogeneity, lack of standardization and insufficient external validation. Future efforts should prioritize prospective validation, explainability and integration into clinical workflows to realize AI's full potential in personalized uro-oncology.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"865-880"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Machine learning-based prognostic prediction for cutaneous malignant melanoma patient survival. 基于机器学习的皮肤恶性黑色素瘤患者生存预测。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-03-15 DOI: 10.1080/14737140.2026.2644385

Yuxin Wang, Jiajia Liu, Huawei Wu, Hui Zhai

{"title":"Machine learning-based prognostic prediction for cutaneous malignant melanoma patient survival.","authors":"Yuxin Wang, Jiajia Liu, Huawei Wu, Hui Zhai","doi":"10.1080/14737140.2026.2644385","DOIUrl":"10.1080/14737140.2026.2644385","url":null,"abstract":"Background: Cutaneous malignant melanoma (CMM) is a highly malignant tumor that necessitates early diagnosis and precise survival prediction. The development of accurate prognostic models is essential for improving patient survival.Research design and methods: This retrospective study analyzed data from 5979 CMM patients in the SEER database (2004-2015), with external validation using the TCGA dataset. Patients were randomly allocated to training and testing sets in a 7:3 ratio. The SMOTE+DeepSurv (DeepSmote) model was compared against seven models, including DeepSurv, XGBoost, Logistic Regression (LR), Support Vector Machine (SVM), Random Forest (RF), K-Nearest Neighbors (KNN), and Decision Tree (DT). Model performance was evaluated using Area Under the Curve (AUC), accuracy, precision, recall, and F1-score.Results: The DeepSmote model demonstrated superior prognostic performance across both SEER and TCGA datasets. On the SEER test set, it achieved an AUC of 0.96, accuracy of 0.95, and F1-score of 0.95 for 1-year prediction. This strong performance was maintained in the external TCGA cohort (AUC: 0.91, accuracy: 0.88, F1-score: 0.87), and consistent superiority was observed for 3- and 5-year predictions, confirming its robustness and generalizability.Conclusion: DeepSmote provides an accurate, generalizable prognostic tool for CMM survival prediction, outperforming other models across multiple datasets and evaluation metrics.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"947-959"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147390048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review. 高选择性酪氨酸激酶抑制剂宗厄替尼在靶向her2突变型NSCLC中的作用：从实验室到临床的回顾

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-02-18 DOI: 10.1080/14737140.2026.2623059

John V Heymach, Sanjay Popat, Egbert F Smit, Petros Christopoulos, David Planchard, Tatsuya Yoshida, Jon Zugazagoitia, Yan Yu, Birgit Wilding

{"title":"The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.","authors":"John V Heymach, Sanjay Popat, Egbert F Smit, Petros Christopoulos, David Planchard, Tatsuya Yoshida, Jon Zugazagoitia, Yan Yu, Birgit Wilding","doi":"10.1080/14737140.2026.2623059","DOIUrl":"10.1080/14737140.2026.2623059","url":null,"abstract":"Introduction: HER2 is mutated in 2-4% of non-small cell lung cancers (NSCLC) and is associated with poor prognosis. Tyrosine kinase inhibitors (TKIs) targeting HER2 have historically been hampered by insufficient efficacy against exon 20 insertion mutations and lack of specificity, resulting in off-target adverse events. Zongertinib is an oral, irreversible HER2-selective TKI that spares wild-type EGFR, thereby minimizing associated toxicities. Zongertinib was recently approved in the United States (accelerated), China (conditional), and Japan for patients with previously treated advanced HER2-mutant NSCLC.Areas covered: This article outlines the discovery and clinical development of zongertinib that led to these approvals. We discuss the first-in-human Beamion LUNG-1 trial (NCT04886804), in which zongertinib demonstrated encouraging and durable activity, with a manageable safety profile, in patients with HER2-mutant advanced NSCLC. Finally, we summarize ongoing clinical trials of zongertinib, including its assessment as first-line treatment for advanced HER2-mutant NSCLC.Expert opinion: Zongertinib is the first oral TKI approved for HER2-mutant NSCLC and will provide patients with a convenient, tolerable and effective treatment option in an area of significant unmet need. Next steps include its potential transition to a first-line setting, identification of additional indications, and development of novel combination regimens.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"797-807"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146117928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From fecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy: how far down the road are we? 从粪便微生物群移植到改善免疫检查点抑制治疗的靶向干预：我们走了多远？

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-01-27 DOI: 10.1080/14737140.2026.2621240

Madieke Kleinhans, Anouk Lissen, Lucy Hewitson, Ger T Rijkers

引用次数: 0

RTsDEN: reverse task attention enabled deep learning model for lung cancer detection using computed tomography. RTsDEN：使用计算机断层扫描检测肺癌的反向任务注意支持深度学习模型。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-06-29 DOI: 10.1080/14737140.2026.2689719

Lyernisha Sundara Raj Retna Bai, Ancilin Joseph, Fernisha Sundara Raj Retna Bai

{"title":"RTsDEN: reverse task attention enabled deep learning model for lung cancer detection using computed tomography.","authors":"Lyernisha Sundara Raj Retna Bai, Ancilin Joseph, Fernisha Sundara Raj Retna Bai","doi":"10.1080/14737140.2026.2689719","DOIUrl":"10.1080/14737140.2026.2689719","url":null,"abstract":"Background: Lung cancer remains the most significant cause of cancer-related death worldwide due to the critical challenges in diagnosis. Despite the promising efforts, the existing models faced challenges in capturing the complex patterns in medical imaging data while minimizing the computational complexity. In this research, the lung cancer detection using Computed Tomography (CT) images is performed using the Reverse Task attention-enabled Distributed Elman convolutional neural Network (RTsDEN) model that helps in mitigating the challenges in existing methods and improving the detection performance for real-time applications.Research design and methods: The proposed model, combining the Reverse Task attention-(RTsAt) module and the distributed Elman concept, significantly contributes to capturing the intricate disease patterns from the complex backgrounds and varying environmental conditions. In addition, the proposed method exploits the adaptive lobe and multigranular nodule segmentation stage to facilitate better understanding and interpretation for accurate diagnosis.Results: Experimental results reveal that the proposed RTsDEN outperforms other existing models by attaining 97.12% accuracy, 98.03% precision 96.22% recall using LUNA 16 dataset and 97.72% accuracy, 98.31% precision, 97.14% recall using the LIDC-IDRI dataset.Conclusion: The research introduces an efficient DL model with an ensemble approach, which significantly influences effective lung cancer detection.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-30"},"PeriodicalIF":3.0,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148271071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The dual role of Schlafen11 in brain tumors: Jekyll and Hyde. Schlafen11在脑肿瘤中的双重作用：化身和化身。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-06-29 DOI: 10.1080/14737140.2026.2695215

Manabu Natsumeda, Masayasu Okada, Satoshi Nakata, Haruhiko Takahashi, Chinatsu Kakinuma, Calixto-Hope G Lucas, Jun Watanabe, Yoshihiro Tsukamoto, Charles G Eberhart, Akiyoshi Kakita, Junko Murai, Makoto Oishi

{"title":"The dual role of Schlafen11 in brain tumors: Jekyll and Hyde.","authors":"Manabu Natsumeda, Masayasu Okada, Satoshi Nakata, Haruhiko Takahashi, Chinatsu Kakinuma, Calixto-Hope G Lucas, Jun Watanabe, Yoshihiro Tsukamoto, Charles G Eberhart, Akiyoshi Kakita, Junko Murai, Makoto Oishi","doi":"10.1080/14737140.2026.2695215","DOIUrl":"10.1080/14737140.2026.2695215","url":null,"abstract":"Introduction: Schlafen11 (SLFN11) has emerged as a powerful biomarker of sensitivity to DNA-damaging agents in various cancers. However, not much is known about its role in brain tumors. Conflicting reports show that it is a biomarker for response to cisplatin and a prognostic factor in some brain tumors, such as medulloblastomas, but can even be a negative prognostic factor in others, like glioblastomas.Areas covered: In this review, we discuss what is known about the various roles of SLFN11 in cancer, with special attention to brain tumors. Specifically, we focus on the seemingly dual role of SLFN11 in brain tumors; positive prognostic in some and negative in others. Additionally, we describe some glioma cases with high SLFN11 expression, often showing aggressive presentation, a good response to initial treatment, and subsequent widespread relapse.Expert opinion: In brain tumors such as medulloblastomas and primary central nervous system lymphomas (PCNSL), when total cell killing can be expected by chemotherapy and/or chemoradiotherapy, high SLFN11 expression is a positive prognostic marker. However, SLFN11 can also be highly expressed in mesenchymal tumors, and in cases where total cell killing cannot be achieved, widespread relapse can accompany an initial response.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":3.0,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma. 胰高血糖素样肽1受体激动剂治疗子宫内膜癌的潜在影响。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-06-24 DOI: 10.1080/14737140.2026.2691887

John P Micha, Randy D Bohart, Bram H Goldstein

{"title":"The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma.","authors":"John P Micha, Randy D Bohart, Bram H Goldstein","doi":"10.1080/14737140.2026.2691887","DOIUrl":"10.1080/14737140.2026.2691887","url":null,"abstract":"Introduction: Endometrial cancer is the most frequently diagnosed gynecologic malignancy. Despite favorable clinical outcomes associated with early-stage disease, advanced or recurrent endometrial cancer is significantly more aggressive and coincides with inauspicious survival rates.Areas covered: Since endometrial cancer often develops in patients with obesity and type 2 diabetes, studies have evaluated metformin as a treatment for this neoplasm. Alternatively, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which mimic the GLP-1 peptide, may confer a decreased risk for endometrial cancer and represent a novel and promising anti-neoplastic therapy. In the current mini-review, we recount the preclinical results abstracted from studies identified via the PUBMED database from 2016-2026, with an emphasis on GLP-1 RAs in the treatment of endometrial cancer.Expert openion: Preclinical data suggest that GLP-1 RAs avert progesterone resistance, augment the effects of hormone therapy, and prevent chemoresistance, not to mention bestow a substantive benefit in the adjuvant treatment of endometrial cancer. Currently, however, the results associated with GLP-1 RAs in treating malignancies are preliminary and warrant further investigation with randomized clinical trials.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-4"},"PeriodicalIF":3.0,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148271011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Central nervous system-related permanent consequences in long-term survivors of pediatric Langerhans cell histiocytosis: a clinical overview and monitoring strategies. 儿童朗格汉斯细胞组织细胞增多症长期幸存者的中枢神经系统相关永久性后果：临床概述和监测策略。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-06-24 DOI: 10.1080/14737140.2026.2693589

Kenichi Sakamoto, Yoko Shioda, Ko Kudo, Akira Morimoto

引用次数: 0

Emerging trends in early-onset gastrointestinal cancers - a comparative review with late-onset cancers. 早发性胃肠道癌症的新趋势-与晚发性癌症的比较回顾。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-06-16 DOI: 10.1080/14737140.2026.2690189

Greta Catani, Luz D Juez, Juan M O Connor, Antonino Spinelli, José Perea

{"title":"Emerging trends in early-onset gastrointestinal cancers - a comparative review with late-onset cancers.","authors":"Greta Catani, Luz D Juez, Juan M O Connor, Antonino Spinelli, José Perea","doi":"10.1080/14737140.2026.2690189","DOIUrl":"10.1080/14737140.2026.2690189","url":null,"abstract":"Introduction: Early-onset gastrointestinal (GI) cancers, defined as those diagnosed before the age of 50, are increasing worldwide, whereas the incidence of late-onset GI cancers has stabilized or declined. These trends highlight the need to better understand age-related differences in disease biology and risk factors.Methods: This narrative review compares early- and late-onset GI malignancies. We discuss differences in epidemiology, molecular and genetic features, clinical presentation, and management strategies. Relevant literature was identified through a non-systematic search of PubMed and additional sources, and selected according to scientific relevance and quality. Publications from 2000 to March 2026 were reviewed, with inclusion of selected landmark historical studies when appropriate.Results: Early-onset tumors are more frequently diagnosed at advanced stages and may reflect the impact of early-life environmental exposures, metabolic dysregulation, and microbiome alterations. Although they share several molecular features with late-onset disease, younger patients often present distinct clinical and survivorship needs, including genetic counseling and fertility preservation. Current treatment strategies remain largely similar across age groups due to limited age-specific evidence.Conclusion: Early-onset GI cancers should be understood within an age-specific biological and environmental framework. Improved understanding of these tumors may support better prevention, earlier diagnosis, and more personalized management strategies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":3.0,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0